In order to get there, however, good data are required through many risk screenings – for example with online surveys – and a diversification of drugs and therapies.
The neurologist emphasized that early detection is key. “There has already been a scientific paradigm shift in this regard,” says Poewe. The focus is no longer exclusively on the diagnosis – if Parkinson’s symptoms such as tremors and stiffness have already occurred – but also primarily on the processes in the brain, which start much earlier. Precise risk screenings are important for this.
According to Poewe, just knowing about risk groups and risk factors, which makes early detection easier, is not enough. You also have to push ahead with the development of drugs and therapies. In the future, these should not only treat the disease, but also significantly slow it down.
Source: Nachrichten
